Table 4.
Treatment-related characteristics of pediatric malignant bone tumor patients
| Variable | Frequency | Percent (%) |
|---|---|---|
| Treatment initiated | ||
| No | 27 | 28.4 |
| Yes | 68 | 71.6 |
| Therapeutic intent (n = 68) | ||
| Curative | 44 | 64.7 |
| Palliative | 24 | 35.3 |
| Treatment completed (n = 68) | ||
| No | 36 | 52.9 |
| Yes | 32 | 47.1 |
| Reason for not completing treatment (n = 35) | ||
| Death | 5 | 14.3 |
| Lost to follow up | 18 | 51.4 |
| Left against medical advice | 9 | 25.7 |
| Palliative care (due to progression) | 3 | 8.6 |
| Type of protocol (n = 67) | ||
| OS1&OS2 protocol | 42 | 61.8 |
| VCD/IE protocol | 15 | 22.1 |
| VCD protocol | 4 | 5.9 |
| Other (VAC, PO palliative) | 7 | 10.3 |
OS1 Cisplatin and doxorubicin, OS2 Cyclophosphamide and Etoposide, VCD/IE Vincristine cyclophosphamide doxorubicin ifosfamide and etoposide, VAC Vincristine Actinomycin and cyclophosphamide